Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this registry study (NCT02292706) followed 1,609 people across eight groups over approximately 240 weeks (around four and a half years). Each group had previously been treated for hepatitis C (a liver virus infection) with one of several different antiviral medicine combinations in an earlier ("parent") trial. The study was tracking three main things over time: whether participants kept undetectable levels of the hepatitis C virus in their blood, whether they experienced any liver-related health events, and whether they developed a type of liver cancer called hepatocellular carcinoma (HCC). The reported data shows that the vast majority of participants across all treatment groups maintained what is called a "sustained virologic response" — meaning the hepatitis C virus remained undetectable in their blood — through to week 240. The reported figures ranged from 98.9% to 100% across the different groups. Regarding liver-related health events, the reported percentages varied more noticeably between groups, ranging from around 15% to approximately 38% of participants experiencing at least one such event over the follow-up period. For the development of new liver cancer (HCC), the reported figures ranged from about 5% to just over 15% depending on the group. On the secondary measures, the reported data shows that no participants in any group had the hepatitis C virus return due to the original virus re-emerging. Two participants across all groups had detectable resistance mutations (changes in the virus that can affect how medicines act on it), and two participants — one each in two different groups — were recorded as having a re-infection with a different hepatitis C virus strain. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 33493697) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Hepatitis C Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing and able to sign a written consent form agreeing to take part in the study.
- You must have either taken part in a previous Gilead-sponsored hepatitis C (HCV) study where you received a treatment that included a drug called sofosbuvir (without interferon), OR — at certain approved locations only — you received an all-oral sofosbuvir-based treatment outside of a clinical study, and have paperwork showing the treatment you received, when you started and finished, and that your treatment was successful.
- You must have successfully cleared the hepatitis C virus after treatment, meaning that the virus was no longer detectable in your blood about 12 weeks after finishing your last dose.
- You must have liver cirrhosis (scarring of the liver) that was confirmed before or during your hepatitis C treatment, and you must not have had a liver transplant after receiving sofosbuvir-based treatment.
Who may not be able to join:
- You will likely not be eligible if you are planning to start a new hepatitis C treatment — including any approved or experimental medicines — during the time this registry study is running.
- You may not be eligible if you have a history of a serious illness or another significant medical condition that could make it difficult to attend follow-up appointments or follow the study's requirements (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gilead Study Director, Gilead Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
11 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Maintaining Sustained Virologic Response (SVR) at Week 240; Percentage of Participants With Any Liver-Associated Events; Percentage of Participants Who Developed Hepatocellular Carcinoma (HCC) Through Week 240
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.